ReviewClinical pharmacokinetics2017
Pharmacokinetics of Rytary
Review in Clinical pharmacokinetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Lessons Learned From a Delayed-Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease.Annals of clinical and translational neurology · 2026Trial
- Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Why dopamine replacement therapy will stay as a cornerstone in the treatment of Parkinson disease: a personal opinion.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Advancing the Treatment of Motor Fluctuations in Parkinson's Disease with a Next-Generation Levodopa/Carbidopa Formulation.Neurology and therapy · 2026Review
- Estimating Human Jejunal Effective Permeability Using Numerical Deconvolution of Oral Solution Concentration Data.Pharmaceutical research · 2026Article
- Beyond Dysphagia in Parkinson's Disease: 3D Printing of Orally Disintegrating Tablets (ODTs) for Optimized Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- "Coordination of Anle138b to Silver Results in Selective Reduction of a C-terminal truncated Alpha-synuclein Protein and Increased Aggregate Size."bioRxiv : the preprint server for biology · 2025Article
- Real-World Analysis of Healthcare Utilization, Treatment Patterns, and Economic Burden in Medicare Beneficiaries with Parkinson's Disease: Implications by Levodopa Formulation and Disease Severity.PharmacoEconomics - open · 2025Article
- Therapeutic drug monitoring in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Management of OFF condition in Parkinson disease.The mental health clinician · 2023Article
- Gait Declines Differentially in, and Improves Prediction of, People with Parkinson's Disease Converting to a Freezing of Gait Phenotype.Journal of Parkinson's disease · 2023Article
- Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation.Clinical parkinsonism & related disorders · 2023Article
- Article
- Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (RytaryParkinson's disease · 2021Article
- Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.Drugs · 2020Review
- Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease.Drugs · 2020Review
- Differential Gait Decline in Parkinson's Disease Enhances Discrimination of Gait Freezers from Non-Freezers.Journal of Parkinson's disease · 2020Article
- Objective impairment of tandem gait in Parkinson's disease patients increases with disease severity.Parkinsonism & related disorders · 2019Article
- Review
- Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease.Frontiers in neurology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a chronic progressive neurological disorder characterized by resting tremor, rigidity, bradykinesia, gait disturbance, and postural instability. Levodopa, the precursor to dopamine, coadministered with carbidopa or benserazide, aromatic amino acid decarboxylase inhibitors, is the most effective and widely used therapeutic agent in the treatment of PD. With continued levodopa treatment, a majority of patients develop motor complications such as dyskinesia and motor 'on-off' fluctuations, which are, in part, related to the fluctuations in plasma concentrations of levodopa. A new extended-release (ER) carbidopa-levodopa capsule product (also referred to as IPX066) was developed and approved in the US as Rytary
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.